Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

Why this paper is included

Supporting source evidence:

Transgenic AZ‐GR, IZ‐VDRE, PZ‐TR, AIZ‐AR, and PAZ‐PPARγ cells were incubated with tested compounds and the model ligands, i.e., dexamethasone (DEX, 100 nM), calcitriol (1α,25‐VD3, 50 nM), 3,5,3′‐triiodothyronine (T3, 10 nM), dihydrotestosterone (DHT, 100 nM), and 15‐deoxy‐δ12,14‐prostaglandin J2 (15d‐PGJ2; 40 μM), respectively. (A) Glucocorticoid receptor; (B) vitamin D receptor; (C) thyroid receptor; (D) androgen receptor; and (H) peroxisome proliferator‐activated receptor gamma (PPARγ). (A: D) The histogram depicts mean ± SD from experiments performed in two consecutive passages of cells. (H), Histogram depicts mean ± SD from one of two independent experiments each performed in triplicate. *P < 0.05, two‐way ANOVA. (E) Human constitutive androstane receptor (hCAR) reporter activity in HEK293T cells.

Source: Characterization of FKK compounds as hPXR, AhR (aryl hydrocarbon receptor), and dual hPXR/AhR agonists. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Study design awaiting verification.

Study design awaiting verification

The available source does not establish a sufficiently clear study design.

Meta-analysis unclear · Blinding unclear / not reported · Mixed research settings

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

LS174T cells were initially purchased from ATCC, and before use, cell line authenticity was validated as previously described (Wang et al, ).

Source: Methods.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

Targeting the pregnane X receptor using microbial metabolite mimicry

Study design awaiting verification · EMBO Molecular Medicine · 2020

Original publication title

Targeting the pregnane X receptor using microbial metabolite mimicry

Zdeněk Dvořák; Felix Kopp; Cait M Costello; Jazmin S Kemp; Hao Li; Aneta Vrzalová; Martina Štěpánková; Iveta Bartoňková; Eva Jiskrová; Karolína Poulíková; Barbora Vyhlídalová; Lars U Nordstroem; Chamini V Karunaratne; Harmit S Ranhotra; Kyu Shik Mun; Anjaparavanda P Naren; Iain A Murray; Gary H Perdew; Julius Brtko; Lucia Toporova; Arne Schön; Bret D Wallace; William G Walton; Matthew R Redinbo; Katherine Sun; Amanda Beck; Sandhya Kortagere; Michelle C Neary; Aneesh Chandran; Saraswathi Vishveshwara; Maria M Cavalluzzi; Giovanni Lentini; Julia Yue Cui; Haiwei Gu; John C March; Shirshendu Chatterjee; Adam Matson; Dennis Wright; Kyle L Flannigan; Simon A Hirota; Ryan Balfour Sartor; Sridhar Mani

© 2020 The Authors. Published under the terms of the CC BY 4.0 license

Original publication · Publisher record · CC BY 4.0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

At a glance

What does the authors’ abstract report?

Abstract

The human PXR (pregnane X receptor), a master regulator of drug metabolism, has essential roles in intestinal homeostasis and abrogating inflammation. Existing PXR ligands have substantial off‐target toxicity. Based on prior work that established microbial (indole) metabolites as PXR ligands, we proposed microbial metabolite mimicry as a novel strategy for drug discovery that allows exploiting previously unexplored parts of chemical space. Here, we report functionalized indole derivatives as first‐in‐class non‐cytotoxic PXR agonists as a proof of concept for microbial metabolite mimicry.

The lead compound, FKK6 (Felix Kopp Kortagere 6), binds directly to PXR protein in solution, induces PXR‐specific target gene expression in cells, human organoids, and mice. FKK6 significantly represses pro‐inflammatory cytokine production cells and abrogates inflammation in mice expressing the human PXR gene. The development of FKK6 demonstrates for the first time that microbial metabolite mimicry is a viable strategy for drug discovery and opens the door to underexploited regions of chemical space.

Authors’ abstract

Abstract

The human PXR (pregnane X receptor), a master regulator of drug metabolism, has essential roles in intestinal homeostasis and abrogating inflammation. Existing PXR ligands have substantial off‐target toxicity. Based on prior work that established microbial (indole) metabolites as PXR ligands, we proposed microbial metabolite mimicry as a novel strategy for drug discovery that allows exploiting previously unexplored parts of chemical space. Here, we report functionalized indole derivatives as first‐in‐class non‐cytotoxic PXR agonists as a proof of concept for microbial metabolite mimicry.

The lead compound, FKK6 (Felix Kopp Kortagere 6), binds directly to PXR protein in solution, induces PXR‐specific target gene expression in cells, human organoids, and mice. FKK6 significantly represses pro‐inflammatory cytokine production cells and abrogates inflammation in mice expressing the human PXR gene. The development of FKK6 demonstrates for the first time that microbial metabolite mimicry is a viable strategy for drug discovery and opens the door to underexploited regions of chemical space.

Publication and source details

Original title: Targeting the pregnane X receptor using microbial metabolite mimicry

Zdeněk Dvořák; Felix Kopp; Cait M Costello; Jazmin S Kemp; Hao Li; Aneta Vrzalová; Martina Štěpánková; Iveta Bartoňková; Eva Jiskrová; Karolína Poulíková; Barbora Vyhlídalová; Lars U Nordstroem; Chamini V Karunaratne; Harmit S Ranhotra; Kyu Shik Mun; Anjaparavanda P Naren; Iain A Murray; Gary H Perdew; Julius Brtko; Lucia Toporova; Arne Schön; Bret D Wallace; William G Walton; Matthew R Redinbo; Katherine Sun; Amanda Beck; Sandhya Kortagere; Michelle C Neary; Aneesh Chandran; Saraswathi Vishveshwara; Maria M Cavalluzzi; Giovanni Lentini; Julia Yue Cui; Haiwei Gu; John C March; Shirshendu Chatterjee; Adam Matson; Dennis Wright; Kyle L Flannigan; Simon A Hirota; Ryan Balfour Sartor; Sridhar Mani

EMBO Molecular Medicine · 2020

* Corresponding author. Tel: +420 585634903; E‐mail: moulin@email.cz
Corresponding author. Tel: +1 215 991 8135; Fax: +1 215 848 2271; E‐mail: sandhya.kortagere@drexelmed.edu
Corresponding author. Tel: +1 718 430 2871; Fax: +1 718 430 8550; E‐mail: sridhar.mani@einstein.yu.edu
†

These authors contributed equally to this work

© 2020 The Authors. Published under the terms of the CC BY 4.0 licensehttps://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.HHS | NIH | National Institute of Environmental Health Sciences (NIEHS) 10.13039/100000066ES030197ES028244HHS | NIH | National Cancer Institute (NCI) 10.13039/100000054CA127231CA 161879DOD | United States Army | MEDCOM | Congressionally Directed Medical Research Programs (CDMRP) 10.13039/100000090PR160167ICTR Pilot Award362520Department of Defense Partnering PIW81XWH-17-1-0479PR160167Diabetes Research Center GrantP30 DK020541Cancer Center GrantP30CA013330CCFA (Crohn's & Colitis Foundation of America) 10.13039/100001063

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-12T17:58:14.052519+00:00

DOI: 10.15252/emmm.201911621 · PMC7136958